Close
RNS Number : 2641U
Hikma Pharmaceuticals Plc
21 November 2019
 

Hikma Pharmaceuticals PLC

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Mr. Al-Husry has a beneficial interest in DKYB Limited, which holds shares in Hikma.  DKYB Limited previously had 1,109,748 Hikma shares pledged to Citibank Switzerland.  On 19 November 2019 the pledge arrangement was changed so that 989,748 shares were pledged to Citibank Jersey and 120,000 shares were pledged to Citibank Switzerland.  Both Citibank Switzerland and Citibank Jersey are ultimately wholly owned by Citigroup Inc.

 

c)

Price(s) and volume(s)

Price(s): £0.00p

Volume(s): 0

d)

Aggregated information

Aggregated volume: 0

Price: £0.00p

e)

Date of the transaction

19 November 2019

f)

Place of the transaction

London

 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

21 November 2019

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBSBDBLSDBGCB